BNP Paribas Financial Markets
OBIO icon

BNP Paribas Financial Markets’s Orchestra BioMed OBIO Stock Holding History

BNP Paribas Financial Markets’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.4K Buy
8,214
+6,758
+464% +$27.6K ﹤0.01% 5047
2026
Q1 		$6.19K Sell
1,456
-15,551
-91% -$66.2K ﹤0.01% 5292
2025
Q4 		$70.6K Buy
17,007
+16,443
+2,915% +$66.3K ﹤0.01% 4530
2025
Q3 		$1.4K Sell
564
-1,841
-77% -$5.08K ﹤0.01% 5201
2025
Q2 		$6.45K Buy
2,405
+570
+31% +$1.66K ﹤0.01% 4930
2025
Q1 		$7.85K Sell
1,835
-2,623
-59% -$13K ﹤0.01% 4782
2024
Q4 		$17.8K Buy
+4,458
New +$23.9K ﹤0.01% 4746

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BNP Paribas Financial Markets's OBIO Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Orchestra BioMed (OBIO) stake by 464% in Q2 2026, buying an estimated $27.6K and bringing the position to 8,214 shares worth $35.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5047.

BNP Paribas Financial Markets first reported a position in OBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $70.6K in Q4 2025. 72 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • BNP Paribas Financial Markets held 8,214 shares of Orchestra BioMed worth $35.4K as of Q2 2026.
  • BNP Paribas Financial Markets bought 6,758 Orchestra BioMed shares in Q2 2026, an estimated $27.6K.
  • Orchestra BioMed made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5047 holding.
  • BNP Paribas Financial Markets first reported a position in Orchestra BioMed in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Orchestra BioMed position peaked at $70.6K in Q4 2025.
  • 72 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.